NCT02099201View on ClinicalTrials.gov

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Healthy Subjects
Interventions
DRUG

ACT-389949 40 mg

DRUG

ACT-389949 200 mg

Predicted dose

DRUG

ACT-389949 800 mg

Predicted dose

DRUG

ACT-389949 (Group C1 dose to be selected)

DRUG

ACT-389949 (Group C2 dose to be selected)

DRUG

Placebo

Trial Locations (1)

BT9 6AD

Celerion, Belfast

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY